VEGF-targeted therapy in renal cell carcinoma: active drugs and active choices (Q36409204)

14 August 2017

1 reference

title

VEGF-targeted therapy in renal cell carcinoma: active drugs and active choices (English)

1 reference

14 August 2017

1 reference

Brian I Rini

1

1 reference

14 August 2017

1 March 2006

1 reference

14 August 2017

Current Oncology Reports

1 reference

14 August 2017

8

1 reference

14 August 2017

2

1 reference

14 August 2017

85-89

1 reference

https://scigraph.springernature.com/pub.10.1007/s11912-006-0041-5

14 August 2017

0 references

cites work

Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS11912-006-0041-5

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis

21 January 2018

1 reference

12 December 2020

Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal

1 reference

12 December 2020

Discovery of 5-[5-fluoro-2-oxo-1,2- dihydroindol-(3Z)-ylidenemethyl]-2,4- dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide, a novel tyrosine kinase inhibitor targeting vascular endothelial and platelet-derived growth factor receptor

1 reference

12 December 2020

Discovery of a novel Raf kinase inhibitor

1 reference

12 December 2020

Vascular permeability factor/vascular endothelial growth factor (VPF/VEGF) delays and induces escape from senescence in human dermal microvascular endothelial cells.

1 reference

12 December 2020

Phase II trial of ZD1839 (IRESSA) in patients with advanced renal cell carcinoma

1 reference

12 December 2020

Genetics of renal-cell carcinoma and evidence for a critical role for von Hippel-Lindau in renal tumorigenesis.

1 reference

12 December 2020

Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis

1 reference

12 December 2020

Endothelial cell death, angiogenesis, and microvascular function after castration in an androgen-dependent tumor: role of vascular endothelial growth factor

1 reference

12 December 2020

Bevacizumab for patients with metastatic renal cancer: an update

1 reference

12 December 2020

Cytokine therapy for metastatic renal cell carcinoma

1 reference

12 December 2020

The biology of vascular endothelial growth factor

1 reference

12 December 2020

Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders

1 reference

12 December 2020

Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis

1 reference

12 December 2020

Mutations of the VHL tumour suppressor gene in renal carcinoma

1 reference

12 December 2020

Hypoxia inducible factor activates the transforming growth factor-alpha/epidermal growth factor receptor growth stimulatory pathway in VHL(-/-) renal cell carcinoma cells

1 reference

12 December 2020

Diverse effects of mutations in exon II of the von Hippel-Lindau (VHL) tumor suppressor gene on the interaction of pVHL with the cytosolic chaperonin and pVHL-dependent ubiquitin ligase activity

1 reference

12 December 2020

Signal transduction via platelet-derived growth factor receptors

1 reference

12 December 2020

Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma

1 reference

12 December 2020

Cancer and Leukemia Group B 90206: A randomized phase III trial of interferon-alpha or interferon-alpha plus anti-vascular endothelial growth factor antibody (bevacizumab) in metastatic renal cell carcinoma

1 reference

12 December 2020

Interferon-alpha and survival in metastatic renal carcinoma: early results of a randomised controlled trial. Medical Research Council Renal Cancer Collaborators

1 reference

12 December 2020

Phase II trial of antiepidermal growth factor receptor antibody C225 in patients with advanced renal cell carcinoma.

1 reference

12 December 2020

A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer

1 reference

12 December 2020

Prospective randomized trial of interferon alfa-2a plus vinblastine versus vinblastine alone in patients with advanced renal cell cancer

1 reference

12 December 2020

A phase II trial of gefitinib (Iressa, ZD1839) in stage IV and recurrent renal cell carcinoma

1 reference

12 December 2020

Transforming growth factor alpha is a target for the von Hippel-Lindau tumor suppressor

1 reference

12 December 2020

Role of transforming growth factor-alpha in von Hippel--Lindau (VHL)(-/-) clear cell renal carcinoma cell proliferation: a possible mechanism coupling VHL tumor suppressor inactivation and tumorigenesis

1 reference

12 December 2020

Long-term response data for 255 patients with metastatic renal cell carcinoma treated with high-dose recombinant interleukin-2 therapy

1 reference

12 December 2020

Frequent somatic mutations and loss of heterozygosity of the von Hippel-Lindau tumor suppressor gene in primary human renal cell carcinomas.

1 reference

12 December 2020

In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship.

1 reference

12 December 2020

Acquired resistance to the antitumor effect of epidermal growth factor receptor-blocking antibodies in vivo: a role for altered tumor angiogenesis

1 reference

12 December 2020

10.1007/S11912-006-0041-5

Identifiers

DOI

1 reference

14 August 2017

1 reference

PubMed ID

16507216